Provention Bio, Inc. (PRVB): Price and Financial Metrics

Provention Bio, Inc. (PRVB): $3.91

-0.05 (-1.26%)

POWR Rating

Component Grades













Add PRVB to Watchlist
Sign Up

Industry: Biotech



in industry


  • Growth is the dimension where PRVB ranks best; there it ranks ahead of 69.98% of US stocks.
  • PRVB's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • PRVB's current lowest rank is in the Stability metric (where it is better than 6.87% of US stocks).

PRVB Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PRVB is 0.01 -- better than merely 7.21% of US stocks.
  • For PRVB, its debt to operating expenses ratio is greater than that reported by merely 5.43% of US equities we're observing.
  • PRVB's price/sales ratio is 348.45; that's higher than the P/S ratio of 98.93% of US stocks.
  • Stocks that are quantitatively similar to PRVB, based on their financial statements, market capitalization, and price volatility, are CRDF, BLDP, RDCM, VERU, and CYTK.
  • PRVB's SEC filings can be seen here. And to visit Provention Bio Inc's official web site, go to

PRVB Valuation Summary

  • 500 - Internal server error
  • PRVB's price/earnings ratio has moved up 13.8 over the prior 38 months.
  • PRVB's price/earnings ratio has moved up 13.8 over the prior 38 months.

Below are key valuation metrics over time for PRVB.

Stock Date P/S P/B P/E EV/EBIT
PRVB 2021-08-31 NA 2.7 -3.4 -2.2
PRVB 2021-08-30 NA 2.6 -3.3 -2.1
PRVB 2021-08-27 NA 2.6 -3.3 -2.1
PRVB 2021-08-26 NA 2.5 -3.2 -2.0
PRVB 2021-08-25 NA 2.6 -3.3 -2.1
PRVB 2021-08-24 NA 2.5 -3.2 -1.9

PRVB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PRVB has a Quality Grade of D, ranking ahead of 10.75% of graded US stocks.
  • PRVB's asset turnover comes in at 0 -- ranking 440th of 681 Pharmaceutical Products stocks.
  • 500 - Internal server error

The table below shows PRVB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0 NA -12.020
2021-03-31 0 NA -9.077
2020-12-31 0 NA -5.010
2020-09-30 0 NA -2.755
2020-06-30 0 NA -2.434
2020-03-31 0 NA -2.583

PRVB Price Target

For more insight on analysts targets of PRVB, see our PRVB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $17.93 Average Broker Recommendation 1.5 (Moderate Buy)

PRVB Stock Price Chart Interactive Chart >

Price chart for PRVB

PRVB Price/Volume Stats

Current price $3.91 52-week high $9.35
Prev. close $3.96 52-week low $3.40
Day low $3.78 Volume 408,352
Day high $3.94 Avg. volume 797,956
50-day MA $4.31 Dividend yield N/A
200-day MA $5.76 Market Cap 250.40M

Provention Bio, Inc. (PRVB) Company Bio

Provention Bio, Inc. operates as a biopharmaceutical company. The Company focuses on development of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated disease. Provention Bio serves patients in the State of New Jersey.

PRVB Latest News Stream

Event/Time News Detail
Loading, please wait...

PRVB Latest Social Stream

Loading social stream, please wait...

View Full PRVB Social Stream

Latest PRVB News From Around the Web

Below are the latest news stories about Provention Bio Inc that investors may wish to consider to help them evaluate PRVB as an investment opportunity.

Provention Bio, Inc's. (PRVB) CEO Ashleigh Palmer on Q4 2021 Results - Earnings Call Transcript

Provention Bio, Inc. (PRVB) Q4 2021 Earnings Conference Call February 24, 2022, 08:00 AM ET Company Participants Robert Doody - VP, IR Ashleigh Palmer - Co-Founder, President, CEO Francisco Leon - Co-Founder & Chief Scientific Officer Jason Hoitt - Chief Commercial Officer Thierry Chauche - Chief Financial Officer Conference Call...

SA Transcripts on Seeking Alpha | February 24, 2022

Provention Bio, Inc. (PRVB) Reports Q4 Loss, Tops Revenue Estimates

Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 6.82% and 1.41%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Provention Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a business update.

Yahoo | February 24, 2022

Provention Bio Q4 2021 Earnings Preview

Provention Bio (NASDAQ:PRVB) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is -$0.46 (+20.7% Y/Y) and the consensus Revenue Estimate is $0.47M Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward....

Seeking Alpha | February 23, 2022

Provention Bio resubmits marketing application for diabetes drug in U.S.

The clinical-stage biopharmaceutical company, Provention Bio (PRVB), is trading ~5% higher in the pre-market after the company announced the resubmission of its marketing application

Seeking Alpha | February 22, 2022

Read More 'PRVB' Stories Here

PRVB Price Returns

1-mo N/A
3-mo -46.58%
6-mo -30.43%
1-year -53.78%
3-year -67.69%
5-year N/A
YTD -30.43%
2021 -66.82%
2020 13.69%
2019 741.81%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5608 seconds.